IN2014DN10680A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10680A
IN2014DN10680A IN10680DEN2014A IN2014DN10680A IN 2014DN10680 A IN2014DN10680 A IN 2014DN10680A IN 10680DEN2014 A IN10680DEN2014 A IN 10680DEN2014A IN 2014DN10680 A IN2014DN10680 A IN 2014DN10680A
Authority
IN
India
Prior art keywords
polymorphic forms
crystalline polymorphic
respiratory
disease
mdt
Prior art date
Application number
Other languages
English (en)
Inventor
Robert O Cook
Eugene R Reynolds
Boris Shekunov
Siead I Zegar
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of IN2014DN10680A publication Critical patent/IN2014DN10680A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN10680DEN2014 2012-06-29 2013-06-28 IN2014DN10680A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (1)

Publication Number Publication Date
IN2014DN10680A true IN2014DN10680A (enExample) 2015-08-28

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10680DEN2014 IN2014DN10680A (enExample) 2012-06-29 2013-06-28

Country Status (17)

Country Link
US (2) US9040569B2 (enExample)
EP (1) EP2867216A4 (enExample)
JP (1) JP2015524391A (enExample)
KR (1) KR20150037946A (enExample)
CN (1) CN104507918A (enExample)
AU (1) AU2013282286A1 (enExample)
BR (1) BR112014032290A2 (enExample)
CA (1) CA2877941A1 (enExample)
EA (1) EA201590124A1 (enExample)
HK (2) HK1203956A1 (enExample)
IL (1) IL236476A0 (enExample)
IN (1) IN2014DN10680A (enExample)
MX (1) MX2014015340A (enExample)
NZ (1) NZ628880A (enExample)
TW (1) TWI516283B (enExample)
WO (1) WO2014005098A2 (enExample)
ZA (1) ZA201409073B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES
EP3233807B1 (de) * 2014-12-18 2019-09-04 MetrioPharm AG Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
JP2018535277A (ja) * 2015-11-30 2018-11-29 ノヴァス・セラピューティクス・インコーポレーテッド 耳科学的予防および処置のための組成物および方法
WO2018071445A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
MX2021001820A (es) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) * 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO1999038508A1 (en) 1998-01-29 1999-08-05 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
EP1545513A2 (en) 2002-08-09 2005-06-29 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1539691A2 (en) 2002-08-09 2005-06-15 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES

Also Published As

Publication number Publication date
TWI516283B (zh) 2016-01-11
TW201416093A (zh) 2014-05-01
KR20150037946A (ko) 2015-04-08
WO2014005098A2 (en) 2014-01-03
WO2014005098A3 (en) 2014-02-27
MX2014015340A (es) 2015-03-05
ZA201409073B (en) 2016-08-31
EP2867216A4 (en) 2015-12-09
US9040569B2 (en) 2015-05-26
IL236476A0 (en) 2015-02-26
NZ628880A (en) 2016-08-26
US20140005239A1 (en) 2014-01-02
JP2015524391A (ja) 2015-08-24
US9504672B2 (en) 2016-11-29
HK1210163A1 (en) 2016-04-15
CN104507918A (zh) 2015-04-08
CA2877941A1 (en) 2014-01-03
HK1203956A1 (en) 2015-11-06
AU2013282286A1 (en) 2015-01-22
US20150209328A1 (en) 2015-07-30
EP2867216A2 (en) 2015-05-06
BR112014032290A2 (pt) 2017-06-27
EA201590124A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
IL216935A0 (en) Process for the preparation of nacre mechano-structured by mechanosynthesis, mechano-structured nacre thus obtained and uses thereof
FR2962731B1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
WO2014072961A3 (en) Polymorphic forms of suvoroxant
IN2014DN10680A (enExample)
HUP1100701A2 (en) Novel process for the preparation of travoprost
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
WO2010079045A3 (en) Crystalline salt forms of flibanserine
PL2797863T5 (pl) Sposób wytwarzania 1,3-butadienu
WO2011100282A3 (en) Imatinib mesylate polymorphs
PL2581193T3 (pl) Sposób wytwarzania implantów lub produktów pośrednich takich implantów, jak również implanty i produkty pośrednie otrzymane tym sposobem
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2014102820A3 (en) Rivaroxaban intermediate and preparation thereof
SG11201404764VA (en) Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative
PL2791201T3 (pl) Sposób wytwarzania określonych funkcjonalnych oligomerów kwasu mlekowego
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
IL229669A0 (en) Process for the preparation of 1,2,3 triazole 4 carboxamide